Related Experiment Video
Updated: Aug 16, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Two distinct functional effects of protein phosphatase inhibitors on guinea-pig cardiac L-type Ca2+ channels
Abstract:
1. The effects of the phosphatase inhibitors okadaic acid and calyculin A on single guinea-pig ventricular L-type Ca2+ channels were studied. The inactive derivative norokadaone was used as a negative control. 2. The two known effects of cAMP-dependent stimulation are mimicked by the phosphatase inhibitors to a varying extent. Only okadaic acid promotes the high-activity gating mode ('mode 2'), while calyculin A increases channel availability to a larger extent. As revealed by kinetic analysis of slow gating, the two phosphatase inhibitors retard a slow rate constant, which is assumed to represent exit from the available state by dephosphorylation. Norokadaone was inactive in both regards. 3. Mode 2 gating elicited by very positive prepulses is augmented by okadaic acid, and mode 2 lifetime is prolonged. Calyculin A fails to affect these parameters. Thus, voltage-facilitated mode 2 gating reveals the same pharmacological properties as the mode 2 sweeps observed using conventional pulse protocols. 4. The results are interpreted in terms of the different sensitivity of protein phosphatase subtypes towards the inhibitors: channel availability appears to be controlled by a phosphorylation site dephosphorylated by a type 1-like phosphatase, while mode 2 gating is coupled to a distinct site, dephosphorylated by a type 2A-like phosphatase.
More Related Videos
Related Concept Videos
Amplifying Signals via Enzymatic Cascade
G-Protein Gated Ion Channels
Sensory organs,...
GPCRs Regulate Adenylyl Cylase Activity
Two...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

